Evidence map›Paper›PMID 39900844›Full record

ArticleNeurotoxicity research2025

Cannabidiol-Induced Autophagy Ameliorates Tau Protein Clearance.

Talita A M Vrechi, Gabriel C Guarache, Rafaela Brito Oliveira, Erika da Cruz Guedes, Adolfo G Erustes, Anderson H F F Leão, Vanessa C Abílio, Antonio W Zuardi, Jaime Eduardo C Hallak, José Alexandre Crippa and 4 more

Abstract read
In one paragraph

Article in Neurotoxicity research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Talita A M VrechiDepartment of Pharmacology, Escola Paulista de Medicina, Universidade Federal de São Paulo, Rua Três de Maio, 100, São Paulo, SP, CEP: 04044-020, Brazil.
Gabriel C GuaracheDepartment of Pharmacology, Escola Paulista de Medicina, Universidade Federal de São Paulo, Rua Três de Maio, 100, São Paulo, SP, CEP: 04044-020, Brazil.
Rafaela Brito OliveiraDepartment of Biological Sciences, Universidade Federal de São Paulo, Diadema Campus, Diadema, SP, Brazil.
Erika da Cruz GuedesDepartment of Pharmacology, Escola Paulista de Medicina, Universidade Federal de São Paulo, Rua Três de Maio, 100, São Paulo, SP, CEP: 04044-020, Brazil.
Adolfo G ErustesDepartment of Pharmacology, Escola Paulista de Medicina, Universidade Federal de São Paulo, Rua Três de Maio, 100, São Paulo, SP, CEP: 04044-020, Brazil.
Anderson H F F LeãoDepartment of Pharmacology, Escola Paulista de Medicina, Universidade Federal de São Paulo, Rua Três de Maio, 100, São Paulo, SP, CEP: 04044-020, Brazil.
Vanessa C AbílioDepartment of Pharmacology, Escola Paulista de Medicina, Universidade Federal de São Paulo, Rua Três de Maio, 100, São Paulo, SP, CEP: 04044-020, Brazil.
Antonio W ZuardiNational Institute for Translational Medicine (INCT-TM, CNPq), Ribeirão Preto, Brazil.
Jaime Eduardo C HallakNational Institute for Translational Medicine (INCT-TM, CNPq), Ribeirão Preto, Brazil.
José Alexandre CrippaNational Institute for Translational Medicine (INCT-TM, CNPq), Ribeirão Preto, Brazil.
Claudia BincolettoDepartment of Pharmacology, Escola Paulista de Medicina, Universidade Federal de São Paulo, Rua Três de Maio, 100, São Paulo, SP, CEP: 04044-020, Brazil.
Rodrigo P Ureshino *Department of Biological Sciences, Universidade Federal de São Paulo, Diadema Campus, Diadema, SP, Brazil.
Soraya S Smaili *Department of Pharmacology, Escola Paulista de Medicina, Universidade Federal de São Paulo, Rua Três de Maio, 100, São Paulo, SP, CEP: 04044-020, Brazil.
Gustavo J S PereiraDepartment of Pharmacology, Escola Paulista de Medicina, Universidade Federal de São Paulo, Rua Três de Maio, 100, São Paulo, SP, CEP: 04044-020, Brazil. gustavo.pereira@unifesp.br.

Funding

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior 001Fundação de Amparo à Pesquisa do Estado de São Paulo 2016/20796-2Fundação de Amparo à Pesquisa do Estado de São Paulo 2017/10863-7Fundação de Amparo à Pesquisa do Estado de São Paulo 2018/06260-8Fundação de Amparo à Pesquisa do Estado de São Paulo 2019/02821-8Fundação de Amparo à Pesquisa do Estado de São Paulo 2020/08840-1
6 · The paper itself

Abstract

Tau is a neuronal protein that confers stability to microtubules; however, its hyperphosphorylation and accumulation can lead to an impairment of protein degradation pathways, such as autophagy. Autophagy is a lysosomal catabolic process responsible for degrading cytosolic components, being essential for cellular homeostasis and survival. In this context, autophagy modulation has been postulated as a possible therapeutic target for the treatment of neurodegenerative diseases. Studies point to the modulatory and neuroprotective role of the cannabinoid system in neurodegenerative models and here it was investigated the effects of cannabidiol (CBD) on autophagy in a human neuroblastoma strain (SH-SY5Y) that overexpresses the EGFP-Tau WT (Wild Type) protein in an inducible Tet-On system way. The results demonstrated that CBD (100 nM and 10 µM) decreased the expression of AT8 and total tau proteins, activating autophagy, evidenced by increased expression of light chain 3-II (LC3-II) protein and formation of autophagosomes. Furthermore, the cannabinoid compounds CBD, ACEA (CB1 agonist) and GW-405,833 (CB2 agonist) decreased the fluorescence intensity of EGFP-Tau WT; and when chloroquine, an autophagic blocker, was used, there was a reversal in the fluorescence intensity of EGFP-Tau WT with CBD (1 and 10 µM) and GW-405,833 (2 µM), demonstrating the possible participation of autophagy in these groups. Thus, it was possible to conclude that CBD induced autophagy in EGFP-Tau WT cells which increased tau degradation, showing its possible neuroprotective role. Hence, this study may contribute to a better understanding of how cannabinoids can modulate autophagy and present a potential therapeutic target in a neurodegeneration model.

Indexed as

AutophagyCannabidioltau ProteinsCell Line, TumorDose-Response Relationship, DrugGreen Fluorescent ProteinsHumansMicrotubule-Associated ProteinsCannabidiolenhanced green fluorescent proteinGreen Fluorescent ProteinsMicrotubule-Associated Proteinstau ProteinsAutophagyCBDNeuroprotectionTau protein

Identifiers

PMID39900844
PMCPMC11790692

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.